Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2019
Context: The Company reported a notice from The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price listing requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document addresses a regulatory listing status issue rather than financial performance.
Material Changes
- Listing Status: The Company received notification that its common stock failed to meet Nasdaq Listing Rule 5550(a)(2) because the minimum bid price was below $1.00 per share for 30 consecutive business days.
- Compliance Period: Nasdaq granted a 180-calendar day compliance period ending November 27, 2019, to regain compliance.
- Trading Status: Shares will continue to be listed and traded on The Nasdaq Capital Market during the compliance period.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to consider available options to resolve the noncompliance but has made no determination regarding its specific response at this time.
Path to Compliance: To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least ten consecutive business days within the grace period.
Contingencies:
- If compliance is not met by November 27, 2019, the Company may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure the deficiency, potentially via a reverse stock split.
- Failure to regain compliance within allotted periods may result in delisting.
- The Company retains the right to appeal a delisting determination to a Nasdaq Hearings Panel.
Risks: There is no assurance the Company will regain compliance or meet other listing criteria. Risks include fluctuations in financial results, liquidity changes, and market price declines.
Investor Verification Checklist
- Verify the current trading price of SLS shares to assess proximity to the $1.00 threshold.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Review the Company's most recent Form 10-K for detailed liquidity and capital resource information not included in this 8-K.
- Track the Company's progress toward the November 27, 2019, compliance deadline.